Daxor Corporation (NASDAQ:DXR) Stock Short Interest Falls 51.5%

Key Points

• Daxor’s short interest fell 51.5% to 3,374 shares as of October 15, representing just 0.1% of shares outstanding and a short-interest ratio of 0.3 days.
• DXR shares recently traded at $9.20, between a 52-week range of $8.40 to $14.76, while trading volume exceeded its average.
• Institutional ownership remains limited at 1.34%, although several funds recently initiated or increased positions. Analyst sentiment is mixed, with one Buy and one Hold rating and an overall “Moderate Buy” consensus.

Daxor Corporation (NASDAQ:DXR - Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 3,374 shares, a decrease of 51.5% from the September 30th total of 6,959 shares. Based on an average daily volume of 12,606 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company's stock are sold short.

Daxor Stock Performance

Shares of DXR traded up $0.28 during mid-day trading on Friday, reaching $9.20. The company's stock had a trading volume of 28,009 shares, compared to its average volume of 11,221. Daxor has a 1-year low of $8.40 and a 1-year high of $14.76. The business has a 50-day simple moving average of $10.40 and a two-hundred day simple moving average of $10.76.

Institutional Investors Weigh In On Daxor

Several hedge funds have recently added to or reduced their stakes in DXR. Susquehanna International Group LLP lifted its stake in shares of Daxor by 97.7% during the 2nd quarter. Susquehanna International Group LLP now owns 27,131 shares of the company's stock worth $275,000 after buying an additional 13,411 shares during the last quarter. Aristides Capital LLC acquired a new position in Daxor in the 1st quarter valued at about $403,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Daxor in the 1st quarter valued at about $245,000. Finally, Crescent Grove Advisors LLC bought a new position in Daxor in the 1st quarter valued at about $104,000. Institutional investors and hedge funds own 1.34% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "hold (c)" rating on shares of Daxor in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Daxor has an average rating of "Moderate Buy".

Daxor Company Profile

Daxor Corporation NASDAQ: DXR is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient's total blood volume, plasma volume, red blood cell volume and hematocrit.

The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient's fluid and blood-volume status can assist treatment decisions.

Daxor markets its technology primarily to hospitals and other healthcare providers and also supports clinical research involving blood-volume measurement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.